Source: Hospital Healthcare Europe, October 2018 The European Commission (EC) had approved the use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) to treat adults with advanced BRAF-mutant melanoma. The EC’s decision is based on results from the Phase 3 COLUMBUS trial, which demonstrated 14.9 months median progression-free survival and 33.6 months median overall survival with the combination […]
Archive | Regulatory
European Commission approves BRAFTOVI and MEKTOVI to treat advanced BRAF-mutant melanoma
Posted in Melanoma News, Regulatory, Publications
NICE turns down Opdivo for adjuvant melanoma therapy
England’s cost effectiveness watchdog NICE has decided not to recommend use of the PD-1 inhibitor
Posted in Melanoma News, Regulatory
Half of European clinical trials haven’t reported results
A new interactive website shows that 49% of clinical trials on the EU clinical trials register have not reported results.
Posted in Melanoma News, Regulatory, Of Interest
Targeted treatment for melanoma to be free on NHS
Hundreds of patients with a type of aggressive skin cancer will be offered a targeted therapy on the NHS in England and Wales, which reduces the risk of it returning.
Posted in Melanoma News, Regulatory
